Search

Author/Creator Chiu, C.

1. ANTI‐TUMOR ACTIVITY OF DARATUMUMAB, A NOVEL HUMAN ANTI CD38 MONOCLONAL ANTIBODY, IN IN VITRO AND IN VIVO MODELS OF B‐CELL NON‐HODGKIN LYMPHOMA. (June 2017)

Authors:
Pérez‐Galán, P.; Vidal‐Crespo, A.; Matas‐Céspedes, A.; Rodriguez, V.; Rossi, C.; Roué, G.; López‐Guillermo, A.; Giné, E.; Campo, E.; Colomer, D.; Wiestner, A.; Bezombes, C.; Balasubramanian, S.; Chiu, C.; Doshi, P.
Journal:
Hematological oncology
Issue:
Volume 35(2017)Supplement 2
Page Start:
46
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

3. DARATUMUMAB, BORTEZOMIB AND DEXAMETHASONE (DVD) VS BORTEZOMIB AND DEXAMETHASONE (VD) IN RELAPSED OR REFRACTORY MULTIPLE MYELOMA (RRMM): EFFICACY AND SAFETY UPDATE (CASTOR). (June 2017)

Authors:
Lentzsch, S.; Weisel, K.; Mateos, M.V.; Hungria, V.; Munder, M.; Nooka, A.; Mark, T.; Quach, H.; Scott, E.; Lee, J.; Sonneveld, P.; Casneuf, T.; Chiu, C.; Qin, X.; Amin, H.; Thiyagarajah, P.; Schecter, J.; Qi, M.; Spencer, A.
Journal:
Hematological oncology
Issue:
Volume 35(2017)Supplement 2
Page Start:
388
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

4. DARATUMUMAB, LENALIDOMIDE, AND DEXAMETHASONE (DRD) VS LENALIDOMIDE AND DEXAMETHASONE (RD) IN RELAPSED OR REFRACTORY MULTIPLE MYELOMA (RRMM): EFFICACY AND SAFETY UPDATE (POLLUX). (June 2017)

Authors:
Bahlis, N.J.; Moreau, P.; Nahi, H.; Plesner, T.; Goldschmidt, H.; Suzuki, K.; Orlowski, R.Z.; Rabin, N.; Leiba, M.; Oriol, A.; Chari, A.; San Miguel, J.; Richardson, P.G.; Usmani, S.; O'Rourke, L.; Wu, K.; Casneuf, T.; Chiu, C.; Qin, X.; Dimopoulos, M.A.
Journal:
Hematological oncology
Issue:
Volume 35(2017)Supplement 2
Page Start:
389
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗